BR112014015016B1 - Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina - Google Patents
Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina Download PDFInfo
- Publication number
- BR112014015016B1 BR112014015016B1 BR112014015016-8A BR112014015016A BR112014015016B1 BR 112014015016 B1 BR112014015016 B1 BR 112014015016B1 BR 112014015016 A BR112014015016 A BR 112014015016A BR 112014015016 B1 BR112014015016 B1 BR 112014015016B1
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- vaccine
- sequence
- homodimeric protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578542P | 2011-12-21 | 2011-12-21 | |
| US61/578,542 | 2011-12-21 | ||
| PCT/EP2012/076404 WO2013092875A1 (en) | 2011-12-21 | 2012-12-20 | Vaccines against hpv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014015016A2 BR112014015016A2 (pt) | 2020-10-27 |
| BR112014015016A8 BR112014015016A8 (pt) | 2023-05-09 |
| BR112014015016B1 true BR112014015016B1 (pt) | 2023-10-03 |
Family
ID=47471832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014015016-8A BR112014015016B1 (pt) | 2011-12-21 | 2012-12-20 | Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9901635B2 (enExample) |
| EP (2) | EP2793937B1 (enExample) |
| JP (1) | JP6258864B2 (enExample) |
| KR (1) | KR102057265B1 (enExample) |
| CN (1) | CN104039833B (enExample) |
| AU (1) | AU2012356969B2 (enExample) |
| BR (1) | BR112014015016B1 (enExample) |
| CA (1) | CA2858963C (enExample) |
| DK (1) | DK2793937T3 (enExample) |
| ES (1) | ES2730718T3 (enExample) |
| HU (1) | HUE043361T2 (enExample) |
| IL (1) | IL233217B (enExample) |
| PT (1) | PT2793937T (enExample) |
| RU (1) | RU2644201C2 (enExample) |
| TR (1) | TR201908199T4 (enExample) |
| WO (1) | WO2013092875A1 (enExample) |
| ZA (1) | ZA201404516B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970466A1 (en) * | 2013-03-15 | 2016-01-20 | Vaccibody AS | Targeting vaccines for veterinary use |
| EP3094652B1 (en) * | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| CA2957128C (en) * | 2014-08-15 | 2023-09-26 | Genexine, Inc. | Methods of treating cervical cancer |
| AU2016309743B2 (en) * | 2015-08-20 | 2019-02-07 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV18 vaccines |
| AU2017205270B2 (en) * | 2016-01-08 | 2024-01-18 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| US12005112B2 (en) | 2017-09-07 | 2024-06-11 | University Of Oslo | Vaccine molecules |
| EP3678698A1 (en) * | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
| JP2023522588A (ja) | 2020-04-09 | 2023-05-31 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | 個別化された治療用抗がんワクチン |
| AU2021261676B2 (en) | 2020-04-24 | 2025-04-24 | Genexine, Inc. | Method for treating cervical cancer |
| US20230165952A1 (en) | 2020-05-01 | 2023-06-01 | Nykode Therapeutics ASA | Betacoronavirus prophylaxis and therapy |
| KR20230164118A (ko) | 2021-03-26 | 2023-12-01 | 니코데 테라퓨틱스 에이에스에이 | 암 치료를 위한 치료 조합 |
| EP4333881A1 (en) | 2021-05-03 | 2024-03-13 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| WO2022238420A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Co-expression of constructs and immunostimulatory compounds |
| CA3215057A1 (en) | 2021-05-10 | 2022-11-17 | Agnete Brunsvik Fredriksen | Co-expression of constructs and immunoinhibitory compounds |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| WO2022238395A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
| WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| AU2022275002A1 (en) | 2021-05-10 | 2023-11-09 | Nykode Therapeutics ASA | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
| US20250049910A1 (en) | 2021-11-03 | 2025-02-13 | Nykode Therapeutics ASA | Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2 |
| EP4608436A1 (en) | 2022-10-25 | 2025-09-03 | Nykode Therapeutics ASA | Constructs and their use |
| EP4615980A1 (en) | 2022-11-09 | 2025-09-17 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| EP1553966B1 (en) * | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| US8932603B2 (en) | 2003-02-25 | 2015-01-13 | Vaccibody As | Modified antibody |
| SI1576967T1 (sl) * | 2004-03-18 | 2008-02-29 | Pasteur Institut | Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe |
| EP1846026A4 (en) | 2005-01-26 | 2008-07-02 | Univ Johns Hopkins | ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN |
| AU2011268934B2 (en) | 2010-06-25 | 2015-09-10 | Nykode Therapeutics ASA | Homodimeric protein constructs |
-
2012
- 2012-12-20 CA CA2858963A patent/CA2858963C/en active Active
- 2012-12-20 US US14/365,536 patent/US9901635B2/en active Active
- 2012-12-20 WO PCT/EP2012/076404 patent/WO2013092875A1/en not_active Ceased
- 2012-12-20 PT PT12809271T patent/PT2793937T/pt unknown
- 2012-12-20 KR KR1020147020468A patent/KR102057265B1/ko active Active
- 2012-12-20 EP EP12809271.5A patent/EP2793937B1/en active Active
- 2012-12-20 JP JP2014548019A patent/JP6258864B2/ja active Active
- 2012-12-20 CN CN201280064089.7A patent/CN104039833B/zh active Active
- 2012-12-20 RU RU2014129788A patent/RU2644201C2/ru active
- 2012-12-20 ES ES12809271T patent/ES2730718T3/es active Active
- 2012-12-20 DK DK12809271.5T patent/DK2793937T3/da active
- 2012-12-20 AU AU2012356969A patent/AU2012356969B2/en active Active
- 2012-12-20 TR TR2019/08199T patent/TR201908199T4/tr unknown
- 2012-12-20 EP EP19166523.1A patent/EP3533462A1/en not_active Withdrawn
- 2012-12-20 HU HUE12809271A patent/HUE043361T2/hu unknown
- 2012-12-20 BR BR112014015016-8A patent/BR112014015016B1/pt active IP Right Grant
-
2014
- 2014-06-18 IL IL233217A patent/IL233217B/en active IP Right Grant
- 2014-06-19 ZA ZA2014/04516A patent/ZA201404516B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ626124A (en) | 2016-07-29 |
| KR102057265B1 (ko) | 2019-12-18 |
| EP3533462A1 (en) | 2019-09-04 |
| ES2730718T3 (es) | 2019-11-12 |
| WO2013092875A1 (en) | 2013-06-27 |
| JP2015508284A (ja) | 2015-03-19 |
| PT2793937T (pt) | 2019-06-05 |
| RU2644201C2 (ru) | 2018-02-08 |
| ZA201404516B (en) | 2017-04-26 |
| CN104039833B (zh) | 2018-01-30 |
| TR201908199T4 (tr) | 2019-06-21 |
| AU2012356969B2 (en) | 2017-05-04 |
| IL233217B (en) | 2019-05-30 |
| HUE043361T2 (hu) | 2019-08-28 |
| CA2858963A1 (en) | 2013-06-27 |
| BR112014015016A8 (pt) | 2023-05-09 |
| EP2793937B1 (en) | 2019-04-10 |
| DK2793937T3 (da) | 2019-07-01 |
| RU2014129788A (ru) | 2016-02-10 |
| AU2012356969A1 (en) | 2014-07-03 |
| EP2793937A1 (en) | 2014-10-29 |
| US20150306217A9 (en) | 2015-10-29 |
| CA2858963C (en) | 2023-05-23 |
| JP6258864B2 (ja) | 2018-01-10 |
| US20150056197A1 (en) | 2015-02-26 |
| US9901635B2 (en) | 2018-02-27 |
| IL233217A0 (en) | 2014-08-31 |
| HK1202442A1 (en) | 2015-10-02 |
| CN104039833A (zh) | 2014-09-10 |
| BR112014015016A2 (pt) | 2020-10-27 |
| KR20140107569A (ko) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014015016B1 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina | |
| AU2021232660B2 (en) | HPV vaccines | |
| EP3441085A1 (en) | Homodimeric protein constructs | |
| TW200844230A (en) | Signaling peptides | |
| US20140234316A1 (en) | Vaccibodies targeted to cross-presenting dendritic cells | |
| JP2019013229A (ja) | 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用 | |
| CN104736173A (zh) | 基于hpv/cyaa的嵌合蛋白及它们在诱导针对hpv感染和hpv诱导的疾病的免疫应答中的应用 | |
| CN113372452B (zh) | 一种细粒棘球绦虫重组蛋白CTLA4-IgV-EgG1Y162及其应用 | |
| US12410214B2 (en) | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein | |
| HK1202442B (en) | Vaccines against hpv | |
| HK40082300A (en) | Hpv vaccines | |
| ES2706058T3 (es) | Constructos de proteínas homodiméricas | |
| NZ626124B2 (en) | Vaccines against hpv | |
| BR112012032922B1 (pt) | Proteína homodimérica, molécula de ácido nucleico, composição farmacêutica, método para a preparação de uma proteína homodimérica, e, vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: NYKODE THERAPEUTICS AS (NO) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: NYKODE THERAPEUTICS ASA (NO) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |